Abstract. Aberrant methylation of CpG islands in the promoter region of genes is a common epigenetic phenomenon found in early cancers. Therefore conducting genome-scale methylation studies will enhance our understanding of the epigenetic etiology behind carcinogenesis by providing reliable biomarkers for early detection of cancer. To discover novel hypermethylated genes in colorectal cancer by genome-wide search, we first defined a subset of genes epigenetically reactivated in colon cancer cells after treatment with a demethylating agent. Next, we identified another subset of genes with relatively down-regulated expression patterns in colorectal primary tumors when compared with normal appearing-adjacent regions. Among 29 genes obtained by cross-comparison of the two gene-sets, we subsequently selected, through stepwise subtraction processes, two novel genes, GABRA1 and LAMA2, as methylation targets in colorectal cancer. For clinical validation pyrosequencing was used to assess methylation in 134 matched tissue samples from CRC patients. Aberrant methylation at target CpG sites in GABRA1 and LAMA2 was observed with high frequency in tumor tissues (92.5% and 80.6%, respectively), while less frequently in matched tumor-adjacent normal tissues (33.6% for GABRA1 and 13.4% for LAMA2). Methylation levels in primary tumors were not significantly correlated with clinicopathological features including age, sex, survival and TNM stage. Additionally, we found that ectopic overexpression of GABRA1 in colon cancer cell lines resulted in strong inhibition of cell growth. These results suggest that two novel hypermethylated genes in colorectal cancer, GABRA1 and LAMA2, may have roles in colorectal tumorigenesis and could be potential biomarkers for the screening and the detection of colorectal cancer in clinical practice.
Introduction
Colorectal cancer (CRC) is one of the most common types of neoplasia in developed countries and is the second leading cause of cancer related death (1, 2) . The mean 5-year survival rate for CRC is estimated to be <10% once metastasis occurs, but it would be greater than 90% if the cancer is found in an early stage (3) . So far, digital rectal exams, fecal occult blood tests, sigmoidoscopy and colonoscopy have been used as acceptable options for early detection of CRC. But these methods lack the needed sensitivity and could be supplemented with a more sensitive and efficient screening assays using novel biomarkers. During carcinogenesis, genetic and epigenetic alterations of tumor suppressor genes are believed to play a pathogenic role (4, 5) . Epigenetic gene silencing of tumor suppressor genes, due to hypermethylation of CpG islands in their promoter region, is known to frequently occur in the early stages of cancer development. Such aberrant events can be utilized as moleculardiagnostic biomarkers for early detection and risk identification in cancer patients (6) .
Methylation status of p16, p14, hMLH1, TSP1, GSTP1 and MGMT genes have been intensively studied in CRC (7) (8) (9) (10) (11) (12) . However, detection of such methylation events in known cancerassociated genes is not yet efficient enough to have clinical usability as early detection markers. Using stool-DNA, for the non-invasive early detection of CRC, studies have recently identified aberrant methylation in genes such as Vimentin, NDRG4, TFPI2 and GATA4/5 which have been shown to have a high frequency in primary tumors of CRC (13) (14) (15) (16) . The discovery of novel hypermethylated genes in tumors has stimulated renewed interest in the field. SUNWOO LEE 1, 7 Development and application of several new strategies using microarray-based technology has allowed for directed, genome-wide discovery of aberrantly methylated genes (17) (18) (19) . Additionally, gene expression profiling of pharmacologically reactivated genes in cancer cell lines, after demethylation by DNA methylation inhibitors, has been successfully used to discover putative genes for methylation targets in several cancers (20) (21) (22) . Therefore, to identify putative genes hypermethylated in CRC, we first performed microarray analysis after global demethylation of colon cancer cell lines. In addition, we used a second expression microarray to profile genes which showed relatively down-regulated patterns in colorectal primary tumors when compared with their normal appearing-adjacent sections. Next following methylation examinations we performed a cross-comparison of the two independent expression microarray data sets, allowing us to efficiently identify a number of putative methylation markers. For diagnostic use, we identified two novel genes, GABRA1 and LAMA2, which are epigenetically inactivated in CRC, as novel methylation markers. These markers were subsequently used for methylation assessment and verification in cell lines and clinical samples.
Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer

Materials and methods
Reagents. All chemical reagents used were purchased from Sigma-Aldrich (MA, USA) unless otherwise noted. HpaII and MspI restriction enzymes were obtained from New England Biolabs (MA, USA). Oligonucleotides were synthesized by Bioneer Inc. (Daejeon, Republic of Korea).
Cells. Human colon cancer cell lines, Caco-2 and HCT116, were purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI-1640 (JBI, Seoul, Republic of Korea) supplemented with 10% fetal bovine serum (JBI) and 100 units/ml of penicillin and 100 µg/ ml of streptomycin (JBI) in a humidified 5% CO 2 incubator at 37˚C.
Clinical specimens. Fresh-frozen primary tumors and paired tumor-adjacent normal tissues of CRC patients were obtained from Soonchunhyang University (Cheonan, Republic of Korea) and Yonsei University Medical Center (Seoul, Republic of Korea). All specimens and pertinent patient information were handled in accordance with the Institutional Review Board. Each tumor specimen was histologically verified by board-certified pathologists. Five colorectal tissue samples from cancer-free individuals were purchased from BioChain (Hayward, CA, USA).
5-aza-2'-deoxycytidine (DAC) treatment to cell lines.
Colon cancer cell lines were plated at the concentration of 1x10 6 cells on 100 mm dishes and treated with 5 µmol/l of DAC for five days. The medium was changed every 24 h after treatment in order to maintain the concentration of DAC at a constant level. For control, cells were treated with an equivalent volume of 50% acetic acid. On day 6, cells were harvested and their genomic DNA and total RNA were extracted with Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
Gene expression analysis. Human 17K cDNA microarrays (Genomictree, Daejeon, Republic of Korea) containing 17,075 samples of human cDNA, which represents 15,724 different genes (Research Genetics, Huntsville, AL, USA), were manufactured as previously described (23) and used in gene expression analysis. The synthesis of the target cDNA probes and the hybridization were performed according to the process previously described (23) . Briefly, each 50 µg of total RNA was mixed with 2 µg of oligo(dT) (24) (GenoTech, Daejeon, Republic of Korea) in 15.4 µl of RNase-free water and incubated at 65˚C for 10 min. After that, single-stranded cDNA was synthesized in the presence of Cy3-dUTP or Cy5-dUTP (1 mM each, NEN Life Science Products, Boston, MA, USA) at 42˚C for 2 h. Total RNA from the match-paired colorectal tissues and from the common reference RNA pools of the eleven cancer cell lines (23) were labeled with Cy5 and Cy3, respectively. Both Cy5 and Cy3-labeled cDNA were purified using a PCR purification kit (Qiagen, Hilden, Germany) and were hybridized onto human 17K cDNA microarrays. The arrays were incubated at 42˚C for 16 h in the humidified hybridization chamber (Genomictree).
Microarray data analysis. The hybridized microarrays were imaged by using an Axon 4000B scanner (Molecular Devices, Synnyvale, CA, USA). The signals and the background fluorescence intensities were calculated for each probe by averaging the intensities of every pixel inside the probe spot region using GenePix Pro 4.0 software (Molecular Devices). Spots of poor quality or indistinguishable signal level from the background were excluded. Data normalization and the selection of differentially-expressed genes were performed using GeneSpring 7.3.1 (Agilent Technologies, Palo Alto, CA, USA).
To analyze differentially-expressed genes between tumor and paired tumor-adjacent normal tissue in colorectal tissues samples, the 'Cross gene error model for replicates' was activated. Gene expression data were normalized in two ways: 'LOWESS' and 'per gene normalization'. In 'per gene normalization', the data from a given gene were normalized to the median expression level of the gene across all samples. The data sets were then assigned into two groups (paired tumor-adjacent tissues and tumor tissues). The expression profiles of the two groups were compared using ANOVA tests (with variances that were not equal, p<0.01) to identify genes that were differentiallyexpressed between them.
To determine reactivation of genes by DAC, gene expression data was normalized using LOWESS. In the analysis of DAC-treated Caco-2 cell compared with control the cut-off value of 2-fold and higher was selected for genes to be consi dered reactivated. The raw DNA microarray data were submitted to the Gene Expression Omnibus (http://www.ncbi.nlm.nih. gov/ geo/) with the following accession number: GSE26799.
HpaII-MspI-PCR assay. The promoter and the 5'-untranslated region (UTR) of the selected genes (3 kb: -2.0-1.0 kb from the transcription start site) were scanned for CpG islands using the MethPrimer program (http://itsa.ucsf.edu/~urolab/methprimer/ index1.html); primers were designed for the HpaII-MspI-PCR assay (24, 25) . To avoid incomplete digestion, 400 ng of genomic DNA was digested with excessive units of HpaII and MspI (80 units each) for 6 h at 37˚C with enzyme buffers recommended by the suppliers and purified using a PCR purification kit (Qiagen). The sequences of the gene-specific primer sets used are shown in Table I . For PCR, 20 ng of digested genomic DNA was used as a template in a 25-µl reaction mixture containing 2.5 U of Taq DNA polymerase (Intron BioTech, Republic of Korea), 2.5 pmoles of each primer and 0.2 mM of each dNTP in PCR buffer (10 mM Tris-HCl at pH 7.5, 50 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT, 10 mM 2-mercaptoethanol). The thermal cycling parameters were optimized for each amplicon. To assess PCR adequacy, the human interferon-2 gene without HpaII site was used as a control. The PCR products from uncut, HpaII-digested and MspI-digested DNA were separated on a 1.5%-agarose gel stained with ethidium bromide and visualized by UV illumination. The band intensity was measured with the Scion image program (Scion Corporation, Maryland, USA). The target region was considered to be methylated if the band intensity of the HpaII amplicon was 2-fold greater than that of the MspI amplicon; otherwise, the sample was considered to be unmethylated.
Quantitative real-time PCR.
Relative gene expression levels of clinical samples were quantified by using the LightCycler system (7900 HT, Applied Biosystems, Foster city, CA, USA), and SYBR Green I dye (Roche Diagnostics, GmbH, Germany).
Real-time PCR and monitoring was performed according to the manufacturer's instructions. Briefly, RNA samples isolated from cell lines and clinical samples were reverse-transcribed, and the expression was quantitated by real-time PCR and normalized by β-actin gene expression. Primer sequences and cycling parameters for GABRA1 and LAMA2 genes are shown in Table Ι . Real-time PCR was repeated three times to verify the results, and the mean mRNA expression was used for subsequent analysis.
Quantitative bisulfite-pyrosequencing analysis. The target 5'-UTR region of GABRA1 and the promoter region of LAMA2 were amplified using the forward primer and the biotinylated reverse primer designed by PSQ Assay Design (Biotage AB, Uppsala, Sweden) ( Table Ι) . Genomic DNA (200 ng) was modified by sodium bisulfite using the EZ DNA methylation kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's instructions. Bisulfite-modified DNA was amplified in a 25-µl reaction volume with the primer set and 5 units of Taq polymerase (Solgent, Inc., Daejeon, Republic of Korea), as described in Table I . The PCR products were visualized on a 1.5%-agarose gel by ethidium bromide staining for PCR verification. Pyrosequencing reactions were performed with 
Construction of mammalian GABRA1-expression vector and cell viability assay.
A full-length cDNA clone for GABRA1 (hMU002273) was provided by the 21C Frontier Human GeneBank (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea). Full-length cDNA (3,440 bp) from the GABRA1 gene (GenBank Accession no. BC030696) was amplified with sequence specific primers; 5'-ATT AGA ATT CGC GAT GAG GAA AAG T-3' for forward and 5'-TAA TCT CGA GGA TCT ATT GAT GTG GTG-3' for reverse, and subcloned into the EcoRI/XhoI site of pcDNA4™/ HisMax vector (Invitrogen).
HCT116 cells (3x10 3 ) were plated in to each well of a 96-well plate, incubated for 24 h, followed by transfection with 0.5 or 0.75 µg/ml of GABRA1-expressing plasmids using Fugene HD transfection reagent (Roche Applied Science, Mannheim, Germany). A pcDNA4™/HisMax vector was transfected as a control. After 48 h of incubation, transfectants were treated with WST-1 reagent (Roche Applied Science), according to the manufacturer's instructions. The cell viability was assayed with an ELISA reader (Benchmark Plus Microplate Spectrophotometer, Bio-Rad, Hercules, USA) at 440 nm.
Results
Identification of candidate methylation target genes by expression microarrays.
The flowchart for step-wise screening is summarized in Fig. 1 . First, Caco-2 cells were treated with DAC then screened for gene reactivation using expression microarray analysis. A total of 1,379 genes were found to be reactivated ≥2.0-fold in the DAC-treated cells when compared to untreated cells.
Second, we performed expression microarray analysis on primary colorectal tumors and match-paired tissues from five CRC patients. This allowed us to obtain a group of genes that demonstrated down-regulation in tumor tissues when compared to adjacent normal tissues. From this group, 238 genes were found to be statistically significant (ANOVA, p<0.01) for down-regulation in tumors. Next, we chose a subset of 29 genes in total from both groups which overlapped as candidates for methy lation target genes. This selection was based on the assumption that gene expression is relatively suppressed in tumor cells due to aberrant methylation in their regulatory regions (Table ΙΙ) .
Out of 29 genes, 11 were excluded because they did not harbor CpG islands in the 5' regulatory region by in silico analysis. Therefore, 18 candidate genes were subjected to methylation assessment in two cell lines using HpaIIMspI-PCR assay. We observed that 8 out of 18 candidate genes were methylated in at least one cell line.
Verification of eight candidate genes by HpaII-MspI-PCR assay in clinical samples.
For verification, we used HpaIIMspI-PCR assay to determine the methylation status of 8 genes in primary tumors and matched adjacent normal tissues from 36 CRC patients, including the 5 samples used in the microarray analysis and the 5 normal tissues from healthy individuals. The methylation patterns of the 8 genes in the clinical samples were subdivided into 3 groups (Fig. 2) . The first group, including SLC6A8, MT1G and FGFR3 showed no specificity due to its high frequency of methylation in all samples and even in normal tissues. Although completely unmethylated in normal tissues, the third group containing RGS2, MTA1 and ID3, showed a lower frequency of methylation in both tumor and matched adjacent normal tissues. Only the second group genes, GABRA1 and LAMA2, showed a relatively high frequency of methylation in primary colorectal tumors (44.4% and 72.2%, respectively) with a lower frequency in adjacent normal tissues. Furthermore, we could not detect any methylation of these genes in normal tissues (Fig. 2) . Therefore, we selected GABRA1 and LAMA2 for further clinical validation due to their potential in discriminating tumor from normal tissue with relatively higher sensitivity and specificity.
Clinical validation of DNA hypermethylation of GABRA1
and LAMA2 by quantitative pyrosequencing analysis. HpaIIMspI-PCR assay provides only qualitative information of methylation status at the site recognized by restriction enzyme Figure 1 . Diagram of systematic approach for discovering CRC-specific hypermethylated target genes. First, two sets of genes were identified via expression microarray analysis (1,379 and 238 genes that were reactivated with DAC treatment in Caco-2 cell and down-regulated in tumors, respectively). Twenty-nine genes were selected by cross-comparison of the gene sets from the microarray experiments. Through a further stepwise filtering process, GABRA1 and LAMA2 genes were finally selected as novel hypermethylated candidates in CRC. Numbers in each box represent the actual number of genes that meet each of the selection criteria. in a given specimen. To overcome this limitation we applied a pyrosequencing-based quantitative methylation assay to estimate not only the presence of methylation but also the level of methy lation fraction of GABRA1 and LAMA2. This assay confirmed that each CpG site in target regions of GABRA1 and LAMA2 had acquired high levels of aberrant methylation in Caco-2 and HCT116 cell lines (Fig. 4C ). We then assessed the level of methylation fraction of two genes in 134 primary tumor and match-paired adjacent normal tissues from CRC patients representing various clinical features (diagnosis parameters, Table ΙΙΙ ) and normal tissues from disease-free individuals (n=4). Methylation levels of GABRA1 and LAMA2 were estimated to range from 5.0% to 69.6% and from 1.1% to 67.2%, respectively, in tumor tissues (T) and from 1.8% to 42.1% and from 1.3% to 38.2%, respectively, in tumor-adjacent normal (NT) tissues while from 15.9% to 17.3% and 13.9% to 18.4% in normal tissues (N) (Fig. 3) . Normal samples demonstrated the GABRA1 and LAMA2 highest MtI values as 17.53% and 18.25%, respectively. These values were used as the thresholds of each gene to determine hypermethylation positivity. We also observed in primary tumor tissues samples a higher frequency of hypermethylation in both genes (92.5% for GABRA1 and 80.6% for LAMA2), while less in adjacent normal tissues (33.6% for GABRA1 and 13.4% for LAMA2) (Table IV) . We evaluated the association of clinical parameters with methylation levels of GABRA1 and LAMA2 genes in 134 CRC patients. There was no significant association between methylation levels and several clinicopathological parameters including age, tumor node metastasis (TNM) stage, gender and survival (Table V) .
Verification of epigenetic regulation of GABRA1 and LAMA2
mRNA expression. First, we evaluated the relative expression level of GABRA1 and LAMA2 mRNA in 5 pairs of tumor and tumor-adjacent normal tissue used in the expression microarray through application of real-time PCR. Expression levels of both GABRA1 and LAMA2 were relatively lower in all of the 5 tumor samples compared to those of the matched tumor-adjacent normal tissues, as predicted by the expression microarray analysis (Fig. 4A) .
In order to confirm that GABRA1 and LAMA2 are transcriptionally suppressed by aberrant DNA methylation, we investigated pharmacological reactivation of regulatory regions in Caco-2 and HCT116 cells following DAC treatment. We observed that reactivation of GABRA1 and LAMA2 genes was induced by DAC treatment (Fig. 4B) . Furthermore, pyrosequencing assessment revealed a slight decrease of the DNA methylation level in the DAC-treated cells compared to the untreated cells: GABRA1 (54.9% vs. 64.0% in Caco-2 and 65.3% vs. 88.2% in HCT116), LAMA2 (33.2% vs. 57.1% in Caco-2 and 27.7% vs. 36.0% in HCT116) (Fig. 4C) .
Inhibition of cell growth in colon cancer cells by ectopic expression of GABRA1.
To examine whether ectopic expression of GABRA1 can inhibit colorectal cancer cell lines, we transfected GABRA1-expressing mammalian vector or an empty vector into HCT116 cells, in which expression of GABRA1 is suppressed by promoter methylation. After 48 h of incubation, three independent cell viability assays consistently showed a significant growth inhibition of GABRA1-transfected cells in a concentration-dependent manner (Fig. 5) .
Discussion
To identify new CRC specific methylation sites in the human genome, which can be utilized as biomarkers for early detection of colorectal cancer, we employed microarray based expression analyses following the concept that down-regulation of gene activity is at least partly attributed to promoter hypermethylation in CRC cells. It is well-recognized in cancer cell lines that hypermethylation in a subset of promoter genes can lead to transcriptional silencing. Additionally, these corresponding genes can be characterized by reactivation following treatment with demethylating agents (4, 20, 26) . Recent studies by Suzuki and Ogawa et al have used pharmacological reactivation to screen for methylation candidate genes in CRC cell lines (20, 21) . However, when we carried out similar experiments using gene expression microarrays, we found such an approach to be less efficient for selection of tumor-specific methylated genes. We hypothesize reactivated genes in the cell line, following treatment with demethylating agents, are composed not only of tumor-specifically methylated genes but also of tissue-specific or tissue culture-specific methylated genes. In this study we sought to increase the sensitivity and specificity of detecting genes that are related to promoter hypermethylation and clinically relevant in CRC. Thus, we developed a refined stepwise screening system to achieve our goals. First, we added an additional set of microarray analysis to obtain a group of genes which are specifically down-regulated in tumors when compared to paired adjacent normal tissues. We then cross-compared both expression microarray data sets to select overlapping genes based on the assumption that they are down-regulated in tumor tissues due to promoter methylation. Through a stepwise filtering procedure (Fig. 1) we have identified two genes, GABRA1 and LAMA2 as methylation markers specific for CRC.
Recently several new genes such as TFPI2, NDRG4, GATA4/5 and Vimentin have been identified as promising methylation markers in stool DNA test for the early detection of CRC (13) (14) (15) (16) . Notably, all of them showed a high frequency of aberrant methylation in primary tumor tissues of CRC patients. Glöckner et al identified TFPI2 as a new marker which revealed a remarkable frequency of aberrant methylation in all CRC adenomas (97%, n=56) and in stages I-IV (99%, n=115) (14) . The prevalence of NDRG4 promoter methylation was 70% (n=83) and 86% (n=184) in two independent sets of primary tumors compared with 4% (n=48) in non-cancerous colon mucosa (15) . The transcription factors GATA4 and GATA5 also evaluated as potential biomarkers were observed in 70% (n=90) and 79% (n=77), respectively, of CRC while 6% (n=88) and 13% (n=100), respectively in normal tissues from non-cancerous controls (16) . Vimentin exon-1 sequence has been intensively studied for its use as a marker in stool DNA testing. Chen et al observed in their earlier studies that this gene was highly methylated in tumors from two independently collected groups of CRC patients, 83% (n=46) and 53% (n=107) (13) . In more recent studies, Zou et al detected Vimentin methylation in 72% of cancers (n=74), 84% of adenoma (n=62) and 11% of normal epithelia (n=70) (27) . In our study, for inter-study comparison, we quantitatively assessed Vimentin methylation status by pyrosequencing in 55 out of 134 randomly selected CRC samples. This demonstrated a comparable frequency of hypermethylation positivity (89.1%, 49/55, Table IV), indicating a good match between our and other clinical samples. From these clinical samples, we observed high methylation frequencies in GABRA1 and LAMA2, 92.5% and 80.6%, respectively (Table IV) demonstrating the prevalence of aberrant methylation in these genes is comparable to those of all genes mentioned above in primary tumors of CRC patients.
Additionally, we found that a small portion of patients demonstrated hypermethylation positivity in at least one gene in adjacent normal tissues (33.6% for GABRA1 and 13.4% for LAMA2, n=134, Table IV ). We speculate that even if tumor-adjacent normal tissue is histologically normal, but has undergone abnormal epigenetic processes, such as aberrant gene promoter methylation as a field-defect (28) suggest that GABRA1 and LAMA2 genes acquired aberrant methylation at an early stage of colorectal tumorigenesis. However, it is possible that aberrant methylation in adjacent normal tissues can be attributed to tumor cell micro-invasion. Further, we report that methy lation level and frequency of GABRA1 and LAMA2 genes in primary tumors was irrespective of clinicopathological features including cancer stage, even though the methylation positivity of both genes were similar across all stages of CRC (Table V) . We believe that this combination of data strongly supports our findings on early markers with high sensitivity and specificity in detecting CRC in patients before clinical symptoms or pathology is present. Thus, further studies are warranted to evaluate this potential clinical application.
It has been reported that GABRA1, a subunit of γ-aminobutyric acid receptor (GABA A R), is directly repressed by c-myc oncoprotein, which plays a critical role in the regulation of cellular proliferation and apoptosis, and that overexpression of this gene leads to the induction of apoptosis (29) . Also, it has been reported that the deletion of GABRA1 locus is involved in the intraurothelial phases of bladder neoplasia (30) . Laminins also play key roles in normal and neoplastic tissues, including cell adhesion and migration, cell proliferation, differentiation, and cell shape (31) . α2 is a subunit of laminin-2 (merosin) and laminin-4 (S-merosin), and capillaries expressing the laminin α2 chain in basement membranes may be considered as early developing vessels in normal and neoplastic human tissues.
In this study, we were able to demonstrate that ectopic overexpression of GABRA1 in colon cancer cell lines did result in strong inhibition of cell growth and proliferation (Fig. 5) . Unfortunately, we were unable to investigate the function of LAMA2 in colon cancer cells due to technical difficulties in cloning. In order to fully investigate the role of GABRA1 and LAMA2 in tumor suppression, other tests such as soft agar colony formation, mobility/invasion assays and, ideally in vivo studies should be conducted, but are currently outside the scope of this study.
We do not clearly know at what point aberrant methylation events occur and what are the molecular mechanisms behind DNA methylation during tumorigenesis. It would be benificial to identify new gene methylation targets to be used as markers for early cancer detection. In order to obtain such optimal targets, a continued effort in identifying new genes with a high frequency of aberrant methylation in cancer patients and early stages of tumorigenesis is needed. The combination of expression microarray analysis in cell lines and clinical tissues confers a powerful advantage in selection of candidate hypermethylated genes for targets.
In this study, we discovered two novel hypermethylated genes in colorectal cancer, GABRA1 and LAMA2, by combining two subsets of genes selected from pharmacologically reactivated genes in colon cancer cell lines and genes down-regulated in colorectal primary tumors. Here, we demonstrate for the first time that the regulatory regions of GABRA1 and LAMA2 are frequently hypermethylated in colorectal cancers. These two genes are potential biomarkers for the screening and the detection of colorectal cancer in clinical practice.
